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Abstract
BACKGROUND: Signaling through stromal cell–derived factor-1α (SDF-1α), strongly secreted by bone marrow stromal
cells and theCXCchemokine receptor 4 (CXCR4) exposedon tumor cells haspivotal roles in proliferation,metastasis, and
tumor cell “dormancy.”Dormancy is associatedwith cytostatic drug resistance and is probably a property of tumor stem
cells andminimal residual disease. Thus, hampering the SDF-1α/CXCR4 cross talk by a CXCR4 antagonist like Plerixafor
(AMD3100) should overcome tumor cell dormancy bymobilization of tumor cells from “sanctuary” niches. Our aimwas to
elucidate the direct effects exerted by SDF-1α and Plerixafor on proliferation, chemosensitivity, and apoptosis of CXCR4-
expressing tumor cells.METHODS: The ability of SDF-1α and Plerixafor to regulate intracellular signaling, proliferation, and
invasion was investigated using two colon cancer cell lines (HT-29 and SW480) with either high endogenous or lentiviral
expression of CXCR4 compared to their respective low CXCR4-expressing counterparts as a model system. Efficacy of
Plerixafor on sensitivity of these cell lines against 5-fluorouracil, irinotecan, or oxaliplatin was determined in a cell viability
assay aswell as stroma-dependent cytotoxicity and apoptosis assays. RESULTS: SDF-1α increased proliferation, invasion,
and ERK signaling of endogenously and lentivirally CXCR4-expressing cells. Exposure to Plerixafor reduced proliferation,
invasion, and extracellular signal-regulated kinase 1/2 (ERK1/2) signaling. Combination of chemotherapy with Plerixafor
showed an additive effect on chemosensitivity and apoptosis in CXCR4-overexpressing cells. An SDF-1–secreting feeder
layer provideda “protective niche” forCXCR4-overexpressing cells resulting in decreased chemosensitivity.CONCLUSION:
CXCR4-antagonistic therapy mobilizes and additionally sensitizes tumor cells toward cytoreductive chemotherapy.
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Introduction
Cytostatic drug resistance is a major obstacle for successful treatment of
metastatic colorectal cancer (CRC) and is strongly associated with a poor
outcome of this disease. Once metastases occur, prognosis significantly
declines [1]; due to drug resistance, monotherapies with 5-fluorouracil
(5-FU), irinotecan, or oxaliplatin in the meantime have been replaced
by combination regimens, e.g., FOLFOX or FOLFIRI [2,3].
The development of drug resistance is supported by the tumor micro-
environment where chemokine interactions appear to play pivotal roles
for tumor progression, metastasis, and tumor cell dormancy. To date,
46 different human chemokines are described as ligands for at least
18 G protein–coupled receptors [4]. High CXC chemokine receptor 4
(CXCR4) expression was observed in primary tumors of CRC patients
(stage IV) and correlated with reduced overall median survival due to liver
metastasis [5,6]. For hematopoietic stem cells (HSCs), the importance
of CXCR4 surface expression was demonstrated for their homing and
engraftment in bone marrow stroma niches through binding to the
CXCR4 ligand chemokine stromal cell–derived factor-1 (SDF-1;
CXCL12) [7]. However, SDF-1 is also secreted by cells of lymph nodes,
liver, and lungs and disperses through the blood flow, thereby sustaining
a gradient for CXCR4-expressing metastatic tumor cells that have
detached from the primary tumor bulk [8–10]. After settlement, metas-
tatic cells are embedded in the stromal microenvironment, where sus-
tained SDF-1 expression [11,12] either provides signals promoting
tumor progression [13] or induces tumor cell dormancy throughCXCR4
signaling [14–16]. Quiescent tumor cells might therefore be protected
in such niches from chemotherapeutic cytotoxicity [17]. There is evi-
dence that the level of CXCR4 expression of tumor cells displays a prog-
nostic measure for disease progression and survival of CRC patients.
Removal of quiescent tumor cells from their niches into the blood
stream is a promising approach to increase the susceptibility of these
cells to chemotherapeutic drugs. In a previous study, combination ther-
apy with CXCR4 antagonists was investigated to enhance the efficacy
of conventional cytoreductive treatment [18]. The synthetic compound
AMD3100 (Plerixafor, Mozobil) was originally developed for the treat-
ment of CD4/CXCR4-mediated human immunodeficiency virus 1 in-
fection. Unexpectedly, it was also seen to trigger a dose-dependent
release of HSC into the peripheral blood of patients and volunteers
[19,20] due to the interruption of the SDF-1/CXCR4 axis between
HSC and the bone marrow microenvironment [21]. In vitro, Plerixafor
inhibited migration, invasion, adhesion, or it prolonged survival of cells
of various tumor entities [22,23].
These capacities in vitro as well as the high clinical efficacy and toler-
ability observed in numerous clinical studies for stem cell mobilization
[24] prompted Plerixafor as a promising add-on to cancer chemo-
therapy, since restored cell cycle activity following mobilization might
enhance the effect of chemotherapy.
In this study, we present both endogenous and lentiviral CXCR4-
overexpressing models in colon cancer cell lines to elucidate the activity
of SDF-1α and Plerixafor on proliferation, chemotherapy-induced sensi-
tivity, and apoptosis. We show for the first time that expression of
CXCR4 enhances chemosensitivity and that treatment with Plerixafor—
besides its mobilization effect—might chemosensitize tumor cells.
Materials and Methods
Cell Lines
The human colon cancer cell lines SW480 and HT-29 were cul-
tured in RPMI 1640 medium (Invitrogen, Karlsruhe, Germany) sup-
plemented with 10% fetal calf serum (FCS; PAA, Pasching, Austria),
penicillin (100 IU/ml; Invitrogen), and streptomycin (100 μg/ml;
Invitrogen) and incubated in a 37°C humidified atmosphere contain-
ing 5% CO2. The human fibrosarcoma cell line HT1080 and the
human embryonic kidney cell line 293T were grown in Dulbecco’s
modified Eagle’s medium (Invitrogen) supplemented with 10% FCS
under the same standard conditions. All cell lines were obtained from
ATCC (Manassas, VA). Mouse FBMD-1 feeder cells were obtained
from Dr D.A. Breems and cultured in particular medium [25] in a
33°C standard incubator.
Lentiviral Vector Construction, Virus Production,
Transduction, and Selection
Construction of lentiviral vectors pHR′SIN–CXCR4–IRES–
enhanced green fluorescent protein (EGFP) [23] and pHR′SINcPPT-
SEW with EGFP as a transgene [26] has already been described.
Lentiviral stocks were produced and titrated as previously explained
[23]. SW480 cells were transduced with lentiviral supernatant of
pHR′SIN-CXCR4-IRES-EGFP or pHR′SINcPPT-SEW in the pres-
ence of polybrene (8 μg/ml; Sigma-Aldrich, Deisenhofen, Germany) at
a multiplicity of infection of 3. Cells were sorted using a FACSVantage
SE cell sorter (BD Biosciences, Heidelberg, Germany) on the basis of
CXCR4 or EGFP expression, either to reach completely transduced
SW480 cell pools or to separate populations of endogenously high
and low CXCR4-expressing HT-29 cells. The presence of endogenous
CXCR4 expression in HT-29 cells has been determined before [23].
Fluorescence-activated Cell Sorting Analyses
The percentage of cells expressing CXCR4 was determined using a
phycoerythrin (PE)–conjugated anti-human CXCR4 antibody (clone
12G5; BD Biosciences). EGFP expression was identified by fluores-
cence intensity. Briefly, cells were incubated with anti-CXCR4 for
30 minutes at 4°C, washed twice, and finally resuspended in 200 μl
of staining medium [phosphate-buffered saline (PBS), 4% FCS]. For
CXCR4 inhibition, cells were pretreated with various concentrations
(1–100 μM) of Plerixafor (Sigma-Aldrich) for 1 hour at 4°C. Acquisition
was carried out on a FACSCalibur flow cytometer (BD Biosciences).
Data were analyzed with the CellQuest software (BD Biosciences).
Western Blot Analyses
SW480 cells were incubated with 20 μMmitogen-activated protein/
extracellular signal-regulated kinase 1/2 (MEK1/2) inhibitor UO126
(Cell SignalingTechnology,Danvers,Massachusetts) or 100μMPlerixafor
before treatment with 100 ng/ml human recombinant SDF-1α
(PeproTech GmbH, Hamburg, Germany) for 5 and 15 minutes. Prep-
aration of protein lysates, electrophoretic separation, and blot analysis
were previously explained [27]. The membranes were probed with pri-
mary antibodies against extracellular signal-regulated kinase 1/2
(ERK1/2), phospho-ERK1/2, and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) overnight at 4°C, incubated with the appropriate
HRP-conjugated secondary antibody (α-rabbit and α-mouse; Cell
Signaling Technology), and visualized by chemiluminescence (ECL;
Amersham Biosciences, Freiburg, Germany).
Invasion Assay
Invasion of HT-29 cells untreated or pretreated with Plerixafor
(100 μM) toward medium containing 100 ng/ml SDF-1α was exam-
ined using Matrigel-coated transwell systems (BD Biosciences and
Corning, Amsterdam, The Netherlands) as described before [23].
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Proliferation Assay
Cells (104) were pretreated with Plerixafor (100 μM) for 1 hour at
4°C, suspended in growth medium, and supplemented with either
human recombinant SDF-1α (100 ng/ml) or Plerixafor in 96-well
plates. Medium was replaced on the second day. Proliferation was
measured after 24, 48, and 72 hours by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) method as described
by Maier et al. [28].
Cytotoxicity and Caspase Assay
Cells (104) were pretreated with Plerixafor (100 μM) for 1 hour
at 4°C and suspended in growth medium in 96-well plates. On the
next day, medium was replaced by medium containing the chemo-
therapeutic drug in increasing concentrations (50–1600 μg/ml 5-FU,
3.2–102.4 μg/ml oxaliplatin, 25–400 μg/ml irinotecan; Sigma-
Aldrich) ± 1, 10, or 100 μM Plerixafor. Following 48-hour incu-
bation at 37°C, cytotoxicity was analyzed by MTT assay (see above).
Half-maximal inhibitory concentration (IC50) values were determined
by the CalcuSyn Software (Biosoft, Cambridge, United Kingdom) as
described by Chou and Talalay [29]. Apoptosis of all SW480- and
HT-29–derived cell lines treated with IC50 of 5-FU obtained in the
cytotoxicity assay was studied using Caspase-Glo 3/7 assay (Promega,
Mannheim, Germany) following the manufacturer’s instructions.
Stroma-dependent Cytotoxicity and Apoptosis Assay
A 96-well plate was coated with PBS/0.1% gelatin solution and a
feeder layer of FBMD-1 cells was established, as described in previous
work [30]. SW480 and HT-29 cells were incubated for 1 hour at
4°C in medium supplemented with Plerixafor (1, 10, or 100 μM).
Subsequently, cell suspensions were added to the preestablished feeder
layer and allowed to migrate for 24 hours at 37°C. Thereafter, medium
supplemented with 1, 10, and 100 μM Plerixafor ± 5-FU in increasing
concentrations (4–16 mg/ml) was added to the respective wells with
PBS as negative control. After further 48 hours of incubation, all cells
were harvested and analyzed by fluorescence-activated cell sorting
(FACS). To differentiate between human colon cancer cells and murine
FBMD-1 cells, the former cells were stained with anti–human MHC
class I–related chain (MIC) A/B (1:10; eBioscience, Frankfurt, Germany)
for 30 minutes at 4°C. In parallel, induction of apoptosis was analyzed
by staining the cells with Annexin V (1:25 diluted in Binding Buffer;
BD Pharmingen) for 15minutes at 4°C. Dead cells were excluded using
propidium iodide (PI, 1 mg/ml; Sigma-Aldrich).
Statistical Analysis
As indicated in the figure legends, the results are presented as
means ± SD and usually represent three independent experiments.
P values (calculated by the two-sided, paired Welch’s t test)≤ .05 were
defined as statistically significant.
Results
Establishment of Endogenously and Lentivirally High
CXCR4-Expressing Colon Cancer Cell Lines
Endogenously CXCR4-expressing colon cancer cell lines. HT-29 cells
(a human colon adenocarcinoma cell line) are endogenously expressing
Figure 1. CXCR4 expression profiles of different colon cancer cell lines. (A) Endogenous expression of CXCR4 in HT-29 cells, sorted by
FACS in two distinct populations HT-29high (displayed in gray) and HT-29low. SW480 cells transduced with (B) HR′SIN-CXCR4-IRES-EGFP
(CXCR4; displayed in gray) and (C) HR′SINcPPT-SEW (EGFP; displayed in gray), both compared to wild-type SW480 cells. Amounts of
CXCR4- and/or EGFP-expressing cells were determined by FACS analyses measuring direct staining with the PE-conjugated anti-human
CXCR4 antibody and/or EGFP autofluorescence. Threshold lines were defined by signals of isotype control (IgG2-PE; BD Pharmingen).
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CXCR4.To separate theCXCR4high- (HT-29high) from the low-expressing
(HT-29low) population, we used flow cytometric sorting (Figure 1A)
to analyze proliferation and chemosensitivity of different CXCR4-
expressing cells.
Lentivirally high CXCR4-expressing colon cancer cell lines. In SW480
cells, overexpression of CXCR4 was achieved by lentiviral transduction
with HR′SIN-CXCR4-IRES-EGFP [23], followed by a CXCR4-
selective FACS analysis sorting forCXCR4-positive cells (SW480CXCR4;
Figure 1B). As a control, SW480 cells were transduced with the vector
HR′SINcPPT-SEW (SW480EGFP) [26] (Figure 1C).
Intracellular Signaling and Cell Invasion Regulated by
SDF-1α and Plerixafor
Activation of ERK1/2 through SDF-1α/CXCR4mediates cell prolifer-
ation, migration, and invasion [31,32]. Thus, we assayed the functionality
of lentivirally overexpressed CXCR4 by analyzing the phosphorylation
status of ERK1/2 after exposure to SDF-1α or Plerixafor, its synthetic
“competitor.” First, SDF-1α induced phosphorylation of ERK1/2 in
CXCR4-expressing SW480 cells within minutes, while the amount of
total ERK1/2 was constant in the cytoplasm. UO126, an inhibitor of
MEK1/2 (the kinase directly upstream of ERK1/2), completely inhibited
phosphorylation of ERK1/2 after exposure to SDF-1α. Plerixafor signifi-
cantly reduced signaling through SDF-1α/CXCR4 in SW480CXCR4
cells only but not in SW480 wild-type cells (Figure 2).
According to previous migration and SDF-1–binding experiments
[30,33], we used a concentration of 100 μM Plerixafor that was shown
to be sufficient for significant inhibition of binding of the specific
antibody to endogenously expressed CXCR4 and to block the recog-
nition of lentivirally expressed CXCR4 almost completely [23].
Previously, we showed that SDF-1α escalated invasion of CXCR4-
expressing SW480 cells [23]. Treatment of HT-29high cells with
SDF-1α resulted in 2.8-fold increase in invasive capacity compared
to HT-29low cells (P < .001), while Plerixafor blocked SDF-1α–
induced invasion (P < .001; Figure 3).
These results highlight that SDF-1α activated intracellular signal-
ing and cell invasion in endogenously CXCR4-expressing HT-29
cells and in lentivirally CXCR4-expressing SW480 cells.
Cell Proliferation under SDF-1α or Plerixafor Exposure
To investigate the effect of the CXCR4 ligand SDF-1α and Plerixafor
on proliferation of the four established colon cancer cell lines (HT-
29high, HT-29low, SW480CXCR4, and SW480EGFP), growth curves
were assessed under SDF-1α or Plerixafor exposure (Figure 4). In all
cell lines, no correlation between CXCR4 expression and proliferation
was discernible.
In HT-29high cells, medium supplemented with SDF-1α slightly
increased proliferation (compared to untreated HT-29high cells). In
SW480CXCR4 cells, proliferation was distinctly increased by SDF-1α
compared to untreated SW480CXCR4 cells (P = .021). In HT-29low
and SW480EGFP cells, the proliferative effect of SDF-1α was marginal
and not significant.
Figure 2. Activation of ERK1/2 signaling downstreamof CXCR4 after
exposure to Plerixafor (1 hour, 100 μM, P100) or UO126 (2 hours,
20 μM) and subsequent SDF-1α (5 or 15 minutes, 100 ng/ml) in
SW480 cells. Western blots with lysates from different preparations
gave similar results. Expression of GAPDHwas used to demonstrate
that equal amounts of protein extracts were loaded.
Figure 3. Cell invasion of HT-29 cells. HT-29high and HT-29low cells were placed in the upper chamber of a transwell migration flask. During
24 hours, cells were allowed to invade through a membrane, previously coated with Matrigel, toward growth medium with or without
chemoattracting SDF-1α (100 ng/ml) in the lower chamber. Pretreatment with 100 μM Plerixafor (P100) inhibited invasion of CXCR4-
expressing cells significantly. Results denote mean ± SD of luminescence signal–derived relative light units of three independent measure-
ments. See text for exact P values.
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Thus, SDF-1α stimulated the proliferation of HT-29high and
SW480CXCR4 cells compared to HT-29low and SW480EGFP cells
(P < .026).
While Plerixafor did not affect proliferation of HT-29high and HT-
29low cells (Figure 4A), it decreased significantly the proliferation rate of
SW480CXCR4 cells (Figure 4B; P = .016). A comparable antiprolifera-
tive effect of Plerixafor was observed in SW480EGFP cells (Figure 4B).
CXCR4 Expression and Chemosensitivity: Combination
Treatment with Cytostatic Drugs ± SDF-1α or Plerixafor
We investigated the ability of CXCR4 expression to modulate
chemosensitivity to cytostatic drugs in combination with SDF-1α
or Plerixafor in the MTT assay. In HT-29 (Figure 5, A–C ) and
SW480 cells (Figure 5, D–F ), the cytotoxicity of increasing concen-
trations of 5-FU (Figure 5, A and D), irinotecan (Figure 5, B and E ),
Figure 4. Impact of SDF-1α or Plerixafor (P100) on proliferation of HT-29high and HT-29low (A) and SW480CXCR4 and SW480EGFP
(B) cell lines. MTT measurements were performed twice in quadruplicate (mean ± SE).
Figure 5. Combination treatment of HT-29high and HT-29low as well as SW480CXCR4 and SW480EGFP cells with cytostatic drugs
and Plerixafor. Tumor cells were treated with increasing concentrations of 5-FU, irinotecan, or oxaliplatin ± 100 μM Plerixafor (P100;
HT-29: A–C; SW480: D–F). Results are presented as mean ± SD of not less than three independent measurements. See text for exact
P values.
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and oxaliplatin (Figure 5, C and F ) was analyzed, and IC50 values
were calculated (Table 1).
Expression of CXCR4 was associated with increased chemo-
sensitivity in all cell lines, independent of the cytostatic drug used
(P < .043; Figure 5 and Table 1). Exposure of CXCR4-expressing
cells to 5-FU plus SDF-1α resulted in a significant decrease of
IC50 values compared to 5-FU alone (P = .049 for HT-29high cells
and P = .001 for SW480CXCR4 cells, respectively; Table 1). This
effect of SDF-1α was also observed in HT-29high cells exposed
to oxaliplatin compared to oxaliplatin alone (P = .038) but not in
SW480CXCR4 cells. A similar effect of SDF-1α was observed in
oxaliplatin-treated HT-29low cells (P = .017) and in 5-FU–treated
SW480EGFP cells (P = .045). SDF-1α showed no effect on irinotecan-
treated cell lines.
Plerixafor (1, 10, and 100 μM) reduced the survival rate of CXCR4-
overexpressing cells in combination with 5-FU and oxaliplatin (P < .011
for HT-29high cells and P < .001 for SW480CXCR4 cells; Figure 5
and Table 1). This Plerixafor effect was also seen in HT-29low
cells in combination with oxaliplatin and in SW480EGFP cells in
combination with all three drugs (Figure 5 and Table 1). The pro-
nounced sensitization of SW480EGFP cells to all three cytostatic drugs
by addition of Plerixafor was emphasized by the dose-response curves
given in Figure 5, D to F .
Lentiviral knockdown of CXCR4 in SW480CXCR4 cells [23]
decreased their sensitivity to 5-FU significantly (P = .003). In these
SW480CXCR4sh cells, SDF-1α and Plerixafor had also a sensitizing
effect toward 5-FU (Table 1).
Altogether, CXCR4 expression increased chemosensitivity of colon
cancer cell lines. In no case, the combination of cytostatic drugs with
SDF-1α or Plerixafor hampered the cytostatic effect but rather in-
creased chemosensitivity.
CXCR4 Expression and 5-FU Induced Apoptosis
To elucidate an impact of CXCR4 expression on apoptosis after
chemotherapy, caspase 3/7 activity was measured following chemo-
therapy with 5-FU ± Plerixafor, using the respective IC50 values of
5-FU. Apoptosis was significantly induced by 5-FU exposure 1.8-fold
(P < .001) in HT-29high cells (Figure 6A) and 3.3-fold (P < .001) in
Table 1. IC50 Values (μg/ml) ± SD of Chemotherapy ± SDF-1α or ± Plerixafor in HT-29 and SW480 Cells.
Chemotherapeutics HT-29low HT-29high SW480EGFP SW480CXCR4 SW480CXCR4sh
5-FU 698 ± 195 201 ± 37 1304 ± 285 266 ± 47 842 ± 81
5-FU + SDF-1α 608 ± 233 149 ± 2 607 ± 95 101 ± 43 468 ± 88
5-FU + Plerixafor (100 μM) 516 ± 56 102 ± 9 398 ± 93 120 ± 37 301 ± 73
5-FU + Plerixafor (10 μM) 474 ± 35 89 ± 12 365 ± 56 155 ± 34
5-FU + Plerixafor (1 μM) 462 ± 45 90 ± 12 305 ± 26 166 ± 18
Irinotecan 60 ± 12 39 ± 5 206 ± 52 74 ± 16
Irinotecan + SDF-1α 45 ± 6 39 ± 6 199 ± 25 102 ± 21
Irinotecan + Plerixafor (100 μM) 52 ± 3 35 ± 3 103 ± 24 53 ± 15
Irinotecan + Plerixafor (10 μM) 41 ± 12 30 ± 7 62 ± 7 33 ± 7
Irinotecan + Plerixafor (1 μM) 38 ± 10 29 ± 8 70 ± 9 37 ± 3
Oxaliplatin 53 ± 5 32 ± 9 80 ± 13 16 ± 5
Oxaliplatin + SDF-1α 32 ± 7 16 ± 6 92 ± 1 12 ± 2
Oxaliplatin + Plerixafor (100 μM) 21 ± 6 10 ± 3 37 ± 12 6 ± 3
Oxaliplatin + Plerixafor (10 μM) 16 ± 6 6 ± 1 35 ± 3 7 ± 2
Oxaliplatin + Plerixafor (1 μM) 24 ± 4 9 ± 3 33 ± 8 7 ± 3
Results have been determined by the medium dose–effect relationship [29] of at least three independent experiments.
Figure 6. Apoptosis of CXCR4-expressing HT-29 (A) and SW480 (B) cells. Cells were treated with the IC50 dose of 5-FU in the respective
cell line [calculated according the results of the MTT assays; Table 1 and Figure 3, A (201 μg/ml) and D (266 μg/ml), respectively] ± 1, 10,
and 100 μM Plerixafor. Results are presented as the mean ± SD of luminescence signal–derived relative light units of four independent
measurements. See text for exact P values.
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SW480CXCR4 cells (Figure 6B) compared to untreated CXCR4-
expressing cells, whereas no effect was seen in HT-29low and
SW480EGFP cells. Combination of 5-FU with Plerixafor resulted
in a stronger induction of apoptosis than monotherapy of CXCR4-
expressing cells (HT-29high only for 100 μM Plerixafor: 1.1-fold in-
crease vs 5-FU alone; SW480CXCR4 for all Plerixafor concentrations
used: 1.2-fold increase vs 5-FU alone). An increased rate of apoptosis
following combination treatment with 5-FU plus Plerixafor versus
5-FU alone was also observed in HT-29low and SW480EGFP cells
(Figure 6).
CXCR4 Expression and Stroma-Dependent
Cytotoxicity/Apoptosis
To mimic drug-induced cytotoxicity and apoptosis in a stromal
environment, murine SDF-1α–producing stromal FBMD-1 cells
were cocultured with CXCR4-expressing colon cancer cells. Chemo-
sensitivity (cytotoxicity) of colon cancer cells and apoptosis (expres-
sion of Annexin V) were determined after treatment with 5-FU (4, 8,
and 16 mg/ml) and Plerixafor (1, 10, and 100 μM). Necrotic human
colon cancer cells were determined by FACS analyses (MIC A/B+/PI+
staining; Figure 7, A and B).
Dose escalation of 5-FU increased cytotoxicity in all cell lines.
Treatment with 4, 8, and 16 mg/ml 5-FU significantly increased
cytotoxicity in CXCR4-expressing HT-29high and SW480CXCR4
cells compared to the respective untreated controls (P < .043).
Cytotoxicity of 5-FU—albeit less pronounced—was also observed
in HT-29low and SW480EGFP cells.
Addition of Plerixafor to 5-FU increased chemosensitivity of
CXCR4-expressing HT-29high cells significantly (P = .012; Fig-
ure 7A). In SW480CXCR4 cells, the combination was marginally
superior to 5-FU alone (Figure 7B). Plerixafor did not sensitize
HT-29low and SW480EGFP cells to 5-FU (Figure 7, A and B).
Noteworthy, stroma-dependent growth necessitated about 10-fold
concentrations of 5-FU compared to the MTT assay. Combination
regimens of 5-FU plus 1 or 10 μM Plerixafor gave comparable results
(data not shown).
Apoptosis, quantified by the percentages of MIC A/B+/Annexin V+
colon cancer cells, also showed a dose-response relationship to 5-FU
(Figure 7, C and D) and was more pronounced in CXCR4-expressing
cells compared to the respective CXCR4 low-expressing counterparts
(HT-29low and SW480EGFP). Plerixafor (100 μM) significantly in-
creased apoptosis in 5-FU–treated cells compared to 5-FU alone (P < .025
for HT-29high and SW480CXCR4 cells). This increase was not ob-
served in HT-29low or SW480EGFP cells. Lower Plerixafor doses (1 and
10 μM) gave comparable results (data not shown).
Thus, CXCR4 expression increased sensitivity to chemotherapy as
assessed by the induction of necrosis and apoptosis in colon cancer cells
in a stromal environment. Coculture with SDF-1–expressing feeder cells
required higher drug concentrations compared to MTT measurements
(without SDF-1 supplement). Plerixafor increased 5-FU–induced cyto-
toxicity and apoptosis.
Discussion
This is the first study to show that expression of CXCR4 enhances
chemosensitivity and that Plerixafor—besides its mobilization effect—
might chemosensitize tumor cells as well. Tumor cells are embedded
into a stromal microenvironment, including fibroblasts, inflammatory
Figure 7. Stroma-dependent cytotoxicity (A, B) and apoptosis (C, D) of HT-29 (A, C) and SW480 (B, D) cells. Colon cancer cells were
seeded on an FBMD-1 feeder layer and treated with 5-FU in increasing concentrations (4–16 mg/ml) ± 100 μM Plerixafor. After 48 hours
of incubation, cells were analyzed by FACS. Chemotherapeutic cytotoxicity and apoptosis were determined by PI and Annexin V staining,
respectively. Human colon cancer cells were characterized with anti–human MIC A/B. Results are presented as the mean ± SD of three
independent measurements. See text for exact P values.
130 CXCR4 Expression and Chemosensitivity Heckmann et al. Translational Oncology Vol. 6, No. 2, 2013
cells, and vascular cells [34], which provide signals either arresting or
promoting tumor progression. Adhesion to stromal cells was shown
to confer resistance by inhibiting drug-induced cell death of tumor cells
and, therefore, was termed cell adhesion–mediated drug resistance
[35,36]. Tumor cells that adhere to stromal cells through CXCR4
are therefore, at least partially, protected from the effects of cytotoxic
chemotherapy. Stromal fibroblasts constitutively secrete SDF-1 into
the tumor microenvironment [11,12], establishing a chemotactic gra-
dient for cells evading the primary tumor. Beyond that, microenviron-
mental factors might protect metastatic tumor cells against drug
cytotoxicity by maintaining dormancy [14–17] or quiescence of tumor
stem cells [37].
In this study, we established endogenously and lentivirally CXCR4-
expressing colon cancer cell lines and investigated intracellular signaling,
cell proliferation, invasion, and chemosensitivity to different cytostatic
drugs with, and without, addition of SDF-1α or Plerixafor.
We showed that treatment of lentivirally CXCR4-overexpressing
SW480 cells with SDF-1α activated ERK1/2 signaling, while pre-
treatment with Plerixafor impaired ERK1/2 activation and, thus, gave
evidence for the functionality of the lentivirally expressed CXCR4.
CXCR4 signaling stimulates the MAPK/MEK/ERK cascade [31]. This
signaling pathway is also known to affect proliferation and invasion of
CRC cells [32]. We observed that colon cancer cell proliferation was
stimulated by SDF-1α. This mitogenic effect was most pronounced
inCXCR4-overexpressing cells andmight be a prognosticmeasure since
CXCR4 is a commonly found chemokine receptor in human cancers
[38]. This observation underlines previous results [39,40] on the
impact of the SDF-1/CXCR4 axis for proliferation of colon cancer
tumor cells.
On the basis of a chemotactic principle [41,42], the secretion of
SDF-1 by various organs [8,43] could be associated with CRC tumor
growth [40] and metastasis. In our previous work [23], we demon-
strated that masking of the SDF-1α binding site at the CXCR4 receptor
by Plerixafor blocked chemotaxis and invasion of several CRC cell lines
[23]. In the present investigation, CXCR4 antagonism by Plerixafor
reduced tumor cell proliferation and invasion (Figures 3 and 4).
CXCR4 has been identified as an HSC marker [44], and its ex-
pression has been linked to chemoresistant phenotypes [45]. In the
present experiments, however, CXCR4 overexpression marked chemo-
sensitivity, while lower chemosensitivity was found in low or marginally
CXCR4-expressing cells.
The stroma-dependent cytotoxicity assay showed that embedding
of colon cancer cells in a stromal feeder layer protected them against drug
cytotoxicity; an approximately 10-fold dose of anticancer drugs—
compared to unembedded colon cancer cells—resulted in similar reduc-
tion of the tumor cell number.
Mobilization of dormant tumor cells from the protective micro-
environment might be a quantum leap in overcoming minimal residual
disease and improve the patients’ prognosis significantly. In a recent
approach in multiple myeloma, it was demonstrated that mobilization
by Plerixafor resulted in an increased sensitivity of multiple myeloma
cells to chemotherapy [46], and thus, an interruption of the CXCR4/
SDF-1α axis and detachment from their niches by Plerixafor sensi-
tized tumor cells to chemotherapy. In an in vitro approach, direct con-
tact with stromal cells protected chronic lymphocytic leukemia B cells
from chemotherapy-induced apoptosis. Blockade of CXCR4 signal-
ing antagonized stroma-mediated interactions and restored chronic
lymphocytic leukemia chemosensitivity [45]. In accordance with these
results, we showed that Plerixafor mobilized CXCR4-expressing colon
cancer cells from the feeder layer and increased their chemosensitivity
compared to cells without Plerixafor treatment.
Increased chemosensitivity after CXCR4 signaling might be a
result of the down-regulation of genes or proteins involved in DNA
damage repair mechanisms or drug efflux pumps. SDF-1/CXCR4
signaling has been described to induce the transactivation of epider-
mal growth factor receptor (EGFR) whereas treatment with Plerixafor
has hampered mitogenic signaling [47]. Concordant with these find-
ings, we observed a distinct EGFR up-regulation in the CXCR4-
overexpressing cells presented here (Heckmann et al., unpublished data)
that might be a marker for chemosensitivity as shown for monoclonal
antibody–induced sensitivity [48].
In summary, we showed that both high endogenous and lentiviral
expression ofCXCR4 in colon cancer cells increased SDF-1α–dependent
proliferation and chemosensitivity to anticancer drugs. Plerixafor increased
the sensitivity of different colon cancer cell lines to cytostatic drugs sig-
nificantly; it mobilized colon cancer cells from stroma embedment,
paving the way for increased chemotherapeutic sensitivity. Altogether,
these results support the view that—in an adjuvant setting—the use of
Plerixafor to interrupt the interaction of CXCR4 with SDF-1α has the
potential to overcome tumor cell dormancy and drug resistance. Our
data suggest that, in addition to chemosensitization of tumor cells by
mobilization from stromal niches (indirect effect), a combination
of chemotherapy plus Plerixafor might further directly improve the
therapeutic effect of anticancer drugs on the mobilized tumor cells.
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